066ATZ is a PIP4K2A/2B inhibitor with human PIP4K2A Ki 100 nM, PIP4K2B Ki 800 nM, CK2a Ki 130 nM, and CK2a2 Ki 40 nM. 066ATZ binds to ATP-binding sites of PIP4K2A and PIP4K2B to block lipid kinase activity. 066ATZ can be used for the research of non-small cell lung cancer[1].
Molecular Weight:
489.56
Formula:
C22H23N11OS
Target:
PI5P4K
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
